
What We’re Reading: Common Asthma Inhaler Discontinued; AI in Health Care; FDA Approves Omalizumab for Food Allergies
Discontinuation of asthma drug leaves patients in search of alternative; FDA’s approach to artificial intelligence (AI) raises opportunities and challenges; landmark FDA approval signals hope for millions with severe food allergies.
Dispute Over Pricing and Distribution of Asthma Medication
Patients are caught in the crossfires of a dispute between a drug company and pharmacy benefit managers (PBMs), with no end in sight,
Navigating the Regulatory Landscape of Artificial Intelligence in Health Care
As artificial intelligence (AI) continues to revolutionize health care, the FDA's shifting stance on regulating AI-driven medical technologies becomes increasingly pivotal,
FDA Greenlights Breakthrough Treatment for Food Allergies
The FDA's recent approval of omalizumab (Xolair) for treating food allergies represents a significant advancement in addressing severe allergic reactions,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.